Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idalopirdine in mild-moderate Alzheimer's disease
NCT02006641Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Feb 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of Idalopirdine in Alzheimer's disease (AD), sponsored by Lundbeck. Started Feb 2014; status: completed.
02
Drugs
Idalopirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02006641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02006641.